While traditional methods for treating cancer, including chemotherapy and radiation, are often effective at killing cancer cells, they can also kill healthy cells, as well. Cancer researchers around the world are searching for more effective therapies that do not compromise patients' long-term health and wellness. One of the most promising research areas is immunotherapy, which has shown great promise in treating many types of cancer.
Immunotherapies, including immune checkpoint modulators and cell therapy, have revolutionized the treatment of many human diseases. They have improved the outcomes of many cancers to a level thought impossible even a few years ago and comprise a new family of treatments that are quickly becoming a foundation of modern medicine. Classic immunotherapies such as vaccines are becoming increasingly important in a world threatened by emerging pathogens and antibodies that target discrete molecules have helped patients control various autoimmune ailments.
The Center for Immunotherapy & Precision Immuno-Oncology (CITI) is a state-of-the-art center dedicated to immunotherapy research, discovery and developmental therapeutics, with the ultimate goal to make precision immuno-oncology available for every patient. Learn more about our mission and goals.
Our program advances state-of-the-art cell engineering and T cell therapy developmental therapeutics, focusing on clinical development and research. We run cell therapy trials and develop new cell therapy approaches.
Our division advances translational immunology research, specializing in the fields of immuno-oncology, auto-immunity, computational immunology and population immunology.
Our program brings enhanced clinical trials correlates and discovery capabilities to Cleveland Clinic and Case Comprehensive Cancer Center for a wide range of basic and clinical topics.
Our program collaborates with the Cleveland Clinic Cancer Center and Case Comprehensive Cancer Center to provide precision approaches, including immunogenomic profiling, and new immunotherapy trials to patients and investigators.
Our program advances state-of-the-art cell engineering and T cell therapy developmental therapeutics, focusing on clinical development and research. We run cell therapy trials and develop new cell therapy approaches.
Learn MoreIt is our ultimate goal to offer immunogenomic profiling to all patients receiving immunotherapy treatment, either through clinical trials or commercial treatments.
Learn MoreThe goal of the Melenhorst lab is to develop potent, safe T cell-based gene therapies for hematologic and solid organ malignancies.
Learn MoreThe Natalie Silver lab is exploring novel ways to reprogram the tumor immune microenvironment to develop therapeutics for head and neck cancers.
Learn MoreThe Ni lab investigates alterations in metabolism-related genes and metabolites could have direct impact in cancer predisposition, tumor progression and immunotherapy treatment response.
Learn MoreDr. Wu tapped into Cleveland Clinic’s network of immune research experts to help land a competitive National Institutes of Health Merit Award.
Activating the protein STING increases tumor-fighting T-cells in preclinical studies but may also increase production of T-cell dampeners.
Up to one in seven melanoma patients are genetically predisposed to the disease, suggesting family history may be a bigger risk factor than sun exposure in some cases.
Exciting investigation and groundbreaking discovery happens every day at Cleveland Clinic. Join our team of expert researchers at the Center for Immunotherapy & Precision Immuno-Oncology.
View Careers